REGENXBIO Financial Statements (RGNX)
|
|
|
|
Report date
|
|
|
01.03.2021 |
01.03.2022 |
31.12.2022 |
28.02.2023 |
27.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
154.6 |
470.3 |
112.7 |
112.7 |
90.2 |
|
84.3 |
|
Operating Income, bln rub |
|
|
-119.2 |
160.0 |
-262.9 |
-262.9 |
-268.1 |
|
-243.8 |
|
EBITDA, bln rub |
? |
|
-96.8 |
169.5 |
-257.0 |
-244.2 |
-239.5 |
|
-225.1 |
|
Net profit, bln rub |
? |
|
-111.3 |
127.8 |
-280.3 |
-280.3 |
-263.5 |
|
-238.8 |
|
|
OCF, bln rub |
? |
|
-54.1 |
218.9 |
|
-207.5 |
-218.4 |
|
-182.3 |
|
CAPEX, bln rub |
? |
|
26.9 |
84.2 |
|
30.7 |
9.96 |
|
2.48 |
|
FCF, bln rub |
? |
|
-80.9 |
134.7 |
|
-238.2 |
-228.4 |
|
-184.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
238.1 |
258.5 |
375.6 |
321.1 |
321.2 |
|
277.1 |
|
Cost of production, bln rub |
|
|
35.7 |
51.8 |
54.5 |
54.5 |
37.2 |
|
51.1 |
|
R&D, bln rub |
|
|
166.3 |
181.4 |
242.5 |
242.5 |
232.3 |
|
201.3 |
|
Interest expenses, bln rub |
|
|
0.771 |
26.3 |
23.3 |
23.3 |
6.86 |
|
4.61 |
|
|
Assets, bln rub |
|
|
708.2 |
1 114 |
833.3 |
833.3 |
574.0 |
|
519.1 |
|
Net Assets, bln rub |
? |
|
377.8 |
764.3 |
516.2 |
516.2 |
311.7 |
|
301.4 |
|
Debt, bln rub |
|
|
72.7 |
86.7 |
94.8 |
94.8 |
89.3 |
|
84.1 |
|
Cash, bln rub |
|
|
475.7 |
457.4 |
364.6 |
364.6 |
275.3 |
|
255.5 |
|
Net debt, bln rub |
|
|
-403.1 |
-370.8 |
-269.8 |
-269.8 |
-186.0 |
|
-171.4 |
|
|
Ordinary share price, rub |
|
|
45.4 |
32.7 |
22.7 |
22.7 |
18.0 |
|
14.2 |
|
Number of ordinary shares, mln |
|
|
37.3 |
42.4 |
43.2 |
43.2 |
43.7 |
|
50.8 |
|
|
Market cap, bln rub |
|
|
1 691 |
1 388 |
979 |
979 |
785 |
|
720 |
|
EV, bln rub |
? |
|
1 288 |
1 017 |
709 |
709 |
599 |
|
549 |
|
Book value, bln rub |
|
|
378 |
764 |
516 |
516 |
312 |
|
301 |
|
|
EPS, rub |
? |
|
-2.98 |
3.01 |
-6.50 |
-6.50 |
-6.02 |
|
-4.70 |
|
FCF/share, rub |
|
|
-2.17 |
3.17 |
0.00 |
-5.52 |
-5.22 |
|
-3.64 |
|
BV/share, rub |
|
|
10.1 |
18.0 |
12.0 |
12.0 |
7.13 |
|
5.93 |
|
|
EBITDA margin, % |
? |
|
-62.6% |
36.0% |
-228.0% |
-216.7% |
-265.4% |
|
-266.9% |
|
Net margin, % |
? |
|
-72.0% |
27.2% |
-248.7% |
-248.7% |
-292.0% |
|
-283.2% |
|
FCF yield, % |
? |
|
-4.79% |
9.71% |
0.00% |
-24.3% |
-29.1% |
|
-25.6% |
|
ROE, % |
? |
|
-29.5% |
16.7% |
-54.3% |
-54.3% |
-84.5% |
|
-79.2% |
|
ROA, % |
? |
|
-15.7% |
11.5% |
-33.6% |
-33.6% |
-45.9% |
|
-46.0% |
|
|
P/E |
? |
|
-15.2 |
10.9 |
-3.49 |
-3.49 |
-2.98 |
|
-3.02 |
|
P/FCF |
|
|
-20.9 |
10.3 |
|
-4.11 |
-3.44 |
|
-3.90 |
|
P/S |
? |
|
10.9 |
2.95 |
8.68 |
8.68 |
8.70 |
|
8.54 |
|
P/BV |
? |
|
4.48 |
1.82 |
1.90 |
1.90 |
2.52 |
|
2.39 |
|
EV/EBITDA |
? |
|
-13.3 |
6.00 |
-2.76 |
-2.90 |
-2.50 |
|
-2.44 |
|
Debt/EBITDA |
|
|
4.16 |
-2.19 |
1.05 |
1.10 |
0.78 |
|
0.76 |
|
|
R&D/CAPEX, % |
|
|
618.9% |
215.5% |
|
789.1% |
2 332% |
|
8 105% |
|
|
CAPEX/Revenue, % |
|
|
17.4% |
17.9% |
0.00% |
27.3% |
11.0% |
|
2.94% |
|
| REGENXBIO shareholders |
